LIFELINE SPAC I OYJ A EO1 (0CD) - Total Liabilities
Based on the latest financial reports, LIFELINE SPAC I OYJ A EO1 (0CD) has total liabilities worth €9.90 Million EUR (≈ $11.57 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore 0CD net asset momentum to track the company's year-over-year net asset growth rate.
LIFELINE SPAC I OYJ A EO1 - Total Liabilities Trend (2021–2025)
This chart illustrates how LIFELINE SPAC I OYJ A EO1's total liabilities have evolved over time, based on quarterly financial data.
LIFELINE SPAC I OYJ A EO1 Competitors by Total Liabilities
The table below lists competitors of LIFELINE SPAC I OYJ A EO1 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Shanghai KEN Tools Co Ltd
SHE:300126
|
China | CN¥219.72 Million |
|
Bukwang Pharm
KO:003000
|
Korea | ₩132.16 Billion |
|
Westwing Group AG
F:WEW
|
Germany | €129.20 Million |
|
Guangzhou Jet Bio-Filtration Co Ltd
SHG:688026
|
China | CN¥513.57 Million |
|
Batavia Prosperindo Int
JK:BPII
|
Indonesia | Rp3.40 Trillion |
|
Shandong Swan Cotton
SHG:603029
|
China | CN¥1.40 Billion |
|
SAB Biotherapeutics Inc
NASDAQ:SABS
|
USA | $21.32 Million |
|
Advanced Ceramic X
TWO:3152
|
Taiwan | NT$437.44 Million |
Liability Composition Analysis (2021–2025)
This chart breaks down LIFELINE SPAC I OYJ A EO1's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 0CD market cap overview.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 11.90 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.09 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.08 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how LIFELINE SPAC I OYJ A EO1's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for LIFELINE SPAC I OYJ A EO1 (2021–2025)
The table below shows the annual total liabilities of LIFELINE SPAC I OYJ A EO1 from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €9.90 Million ≈ $11.57 Million |
-16.81% |
| 2024-12-31 | €11.90 Million ≈ $13.91 Million |
+2875.00% |
| 2023-12-31 | €400.00K ≈ $467.64K |
-99.60% |
| 2022-12-31 | €99.32 Million ≈ $116.11 Million |
+1.02% |
| 2021-12-31 | €98.32 Million ≈ $114.94 Million |
-- |
About LIFELINE SPAC I OYJ A EO1
Canatu Oyj develops and sells carbon nanotubes (CNTs) and related products, and manufacturing equipment for the semiconductor, automotive, and medical diagnostics industries in Finland, the United States, Japan, and Taiwan. The company offers custom CNT synthesis reactors; CNT membrane for high-power EUV lithography and X-Ray filter applications; EUV pellicies to protect photomask for contaminati… Read more